Drug Profile

ISS-peanut allergen conjugate - Dynavax

Alternative Names: Ara h 2-ISS allergen conjugate

Latest Information Update: 13 Feb 2026

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator Dynavax Technologies
Class Allergens; Antiallergics; Food allergy immunotherapies; Glycoproteins; Oligonucleotides
Mechanism of Action Immunomodulators

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity Yes

Highest Development Phases

No development reported Peanut hypersensitivity

Most Recent Events

10 Feb 2026 Dynavax Technologies has been acquired by Sanofi
04 Nov 2017 No recent reports of development identified for preclinical development in Peanut-hypersensitivity in USA
20 Jul 2007 This programme is still in active development

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com